The short answer
Avoid adding oral kava while taking gefitinib without the cancer team’s review. Both the supplement evidence and gefitinib’s product information raise liver concerns, although an exact combined risk has not been measured.
What this answer covers
Oral kava preparations with oral gefitinib. Solvent, cultivar, plant part and mixtures can differ.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- gefitinib
Check the exact treatment
This review concerns oral gefitinib tablets used for selected EGFR-mutated lung cancers. The prescribed tablet and dosing plan matter. Follow the cancer team’s instructions; food, acid reducers and supplements should be reviewed together.
What is known about the supplement
A causality assessment of selected liver-injury reports included water-based kava preparations as well as other extracts and mixtures. This is not a population risk estimate, and product quality, other ingredients and other exposures complicate attribution.
Keep preparation and route separate
A water-based preparation is not automatically free of liver concerns. Reports have involved several kinds of kava products, but this does not mean every user develops injury. The exact bottle and all other medicines should be reviewed together.
Follow the liver-monitoring plan
Gefitinib requires periodic liver tests. Tell the team about supplements already used and promptly report yellowing eyes or skin, dark urine, or persistent nausea and loss of appetite. A few hours between doses has not been shown to prevent liver injury, and you should not adjust cancer treatment yourself.
Evidence and practical considerations
Side effects & toxicity
Supplement-specific liver injury supports a conditional precaution during a medicine with its own hepatotoxicity warning.
- Exact scope
- Oral kava preparations with oral gefitinib. Solvent, cultivar, plant part and mixtures can differ. with RxNorm 328134 IN gefitinib. Current exact oral product: Gefitinib oral tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
- Medication form and route
- Oral
What remains uncertain
- No exact kava-gefitinib clinical interaction study. Conditional liver-risk precaution based on separate evidence; no measured additive incidence or validated spacing.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the exact oral formulation.
Six-hour antacid separation; CYP3A induction can lower exposure; periodic liver monitoring.
How this applies: RxNorm 328134 IN gefitinib. Current exact oral product: Gefitinib oral tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 14 selected reports assessed for causality.
Possible hepatotoxicity was not limited to organic-solvent extracts.
How this applies: Exact reported preparation, population and endpoints; transfer to gefitinib explicitly limited.
Abstract-only selected cases and causality assessment, not incidence or gefitinib co-use; product quality and co-exposures limit attribution.
Source 3: Original official botanical guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of kava preparations.
Rare severe liver injury reported across preparations; causes and susceptibility remain uncertain.
How this applies: Supplement-specific precaution.
Not a quantified gefitinib combination risk.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
gefitinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 7e17c78ee4577de9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.